Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

Regulation of Hematopoietic Stem Cells

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...

Hematopoiesis

Hematopoiesis

The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Overview of Hematopoiesis

Overview of Hematopoiesis

Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A randomized clinical study comparing trabectedin combined with regional hyperthermia with trabectedin in patients with advanced soft tissue sarcoma: HyperTET, a German Interdisciplinary Sarcoma Group trial.

ESMO open·2026

Same author

[Multimodal treatment of sarcomas: standards and new aspects in pharmacological and radio-oncological treatment].

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen·2019

Same author

Regional deep hyperthermia: quantitative evaluation of predicted and direct measured temperature distributions in patients with high-risk extremity soft-tissue sarcoma.

International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·2019

Same author

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.

Annals of oncology : official journal of the European Society for Medical Oncology·2018

Same author

Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'.

Annals of oncology : official journal of the European Society for Medical Oncology·2017

Same author

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.

Annals of oncology : official journal of the European Society for Medical Oncology·2017

Same journal

Der Internist·2024

Same journal

Der Internist·2024

Same journal

Der Internist·2024

Same journal

Der Internist·2024

Same journal

Der Internist·2024

Same journal

Der Internist·2024

See all related articles

Search research articles

Related Experiment Video

Updated: May 8, 2026

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

[Hemato-oncological diseases].

L H Lindner¹, W Hiddemann

¹Medizinische Klinik und Poliklinik III, Klinikum der Universität München, Marchioninistr. 15, 81377, München, Deutschland, lars.lindner@med.uni-muenchen.de.

|August 31, 2013

Summary

This summary is machine-generated.

Diagnosing rare blood disorders like acquired coagulation inhibitors, TTP-HUS, hairy cell leukemia, and GIST is crucial for effective treatment. Prompt diagnosis and targeted therapies significantly improve patient outcomes.

More Related Videos

Homing of Hematopoietic Cells to the Bone Marrow

Homing of Hematopoietic Cells to the Bone Marrow

Published on: March 18, 2009

Related Experiment Videos

Last Updated: May 8, 2026

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

Homing of Hematopoietic Cells to the Bone Marrow

Homing of Hematopoietic Cells to the Bone Marrow

Published on: March 18, 2009

Area of Science:

Hematology
Oncology
Internal Medicine

Context:

Acquired inhibitors of coagulation, thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP-HUS), hairy cell leukemia, and gastrointestinal stromal tumors (GIST) are distinct life-threatening conditions.
Accurate diagnosis is critical for effective management and improved patient outcomes.

Purpose:

To outline diagnostic indicators and essential treatments for several rare and severe hematological and oncological disorders.
To emphasize the importance of timely and accurate diagnosis in managing these complex diseases.

Summary:

Acquired inhibitors of coagulation present with hemorrhagic diathesis and prolonged aPTT, requiring immunosuppression or factor substitution. TTP-HUS is diagnosed via Coombs-negative hemolytic anemia, thrombocytopenia, and fragmentocytes, treated with plasma exchange. Hairy cell leukemia shows pancytopenia and splenomegaly, with CD103 positivity, treated with purine analogs. GIST, driven by KIT/PDGFRA mutations (CD117+), is treated with tyrosine kinase inhibitors.

Impact:

Timely diagnosis and initiation of appropriate therapies, such as immunosuppression for coagulation inhibitors, plasma exchange for TTP-HUS, purine analogs for hairy cell leukemia, and tyrosine kinase inhibitors for GIST, are essential for improving patient survival and quality of life.